{"id":9136,"date":"2026-11-09T11:51:12","date_gmt":"2026-11-09T06:21:12","guid":{"rendered":"https:\/\/lakshmishree.com\/news\/?p=9136"},"modified":"2026-11-09T11:51:12","modified_gmt":"2026-11-09T06:21:12","slug":"divis-laboratories-q2-results","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/news\/divis-laboratories-q2-results\/","title":{"rendered":"Divi&#8217;s Laboratories Q2 Results : Net Profit Jumps 63.6% to \u20b91,127 Crore, Revenue Rises 35.4%"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Divi&#8217;s Laboratories Limited reported a strong financial performance for the second quarter of FY27, with consolidated net profit increasing 63.6% year-on-year (YoY) to \u20b91,127 crore, compared with \u20b9689 crore in the corresponding quarter of the previous financial year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The pharmaceutical company&#8217;s revenue from operations grew 35.4% YoY to \u20b93,676 crore in Q2 FY27, against \u20b92,715 crore in Q2 FY26. The growth in revenue and profitability reflects higher business activity and improved operating performance during the September quarter.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Consolidated total income stood at \u20b93,770 crore during Q2 FY27, compared with \u20b92,860 crore in the year-ago period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Divi&#8217;s Laboratories Q2 Results : EBITDA Increases 76%<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Divi&#8217;s Laboratories recorded a significant improvement in operating performance during the quarter. EBITDA increased 76% YoY to \u20b91,566 crore, compared with \u20b9888 crore in Q2 FY26.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The EBITDA margin expanded to 42.6% from 32.7% in the corresponding quarter last year, reflecting an improvement of approximately 990 basis points.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s operating profit growth outpaced revenue growth, indicating stronger operating leverage during the reporting period.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Other Financial Highlights<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The company&#8217;s other income declined to \u20b994 crore in Q2 FY27 from \u20b9145 crore in the year-ago quarter.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tax expense increased to \u20b9378 crore from \u20b9223 crore in Q2 FY26. The company also reported a foreign exchange gain of \u20b924 crore during the quarter, compared with \u20b963 crore in the corresponding period last year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Despite the decline in other income and higher tax expenses, the company recorded substantial growth in consolidated net profit, supported by improved operating performance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Divi&#8217;s Laboratories H1 FY27 Performance<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For the first half of FY27, Divi&#8217;s Laboratories reported consolidated total income of \u20b96,907 crore, compared with \u20b95,389 crore in H1 FY26.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Consolidated profit after tax increased to \u20b92,029 crore from \u20b91,234 crore in the corresponding six-month period of the previous financial year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The company reported a foreign exchange gain of \u20b917 crore during H1 FY27, compared with \u20b9102 crore in the year-ago period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On a standalone basis, total income for H1 FY27 stood at \u20b96,765 crore, while profit after tax increased to \u20b92,031 crore from \u20b91,253 crore in H1 FY26.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Divi&#8217;s Laboratories Q2 FY27: Key Financial Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue from operations:<\/strong> \u20b93,676 crore, up 35.4% YoY.<\/li>\n\n\n\n<li><strong>Consolidated total income:<\/strong> \u20b93,770 crore, compared with \u20b92,860 crore.<\/li>\n\n\n\n<li><strong>Consolidated net profit:<\/strong> \u20b91,127 crore, up 63.6% YoY.<\/li>\n\n\n\n<li><strong>EBITDA:<\/strong> \u20b91,566 crore, up 76% YoY.<\/li>\n\n\n\n<li><strong>EBITDA margin:<\/strong> 42.6%, compared with 32.7% in Q2 FY26.<\/li>\n\n\n\n<li><strong>Other income:<\/strong> \u20b994 crore, compared with \u20b9145 crore.<\/li>\n\n\n\n<li><strong>H1 FY27 total income:<\/strong> \u20b96,907 crore.<\/li>\n\n\n\n<li><strong>H1 FY27 net profit:<\/strong> \u20b92,029 crore.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Divi&#8217;s Laboratories Q2 Results : Business Outlook<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Divi&#8217;s Laboratories&#8217; September-quarter performance reflects strong growth in revenue and operating profitability. The expansion in EBITDA margin, alongside higher net profit, highlights the improvement in the company&#8217;s operating performance during the quarter.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Going forward, investors will monitor the company&#8217;s revenue growth, operating margins, product demand and performance across its pharmaceutical manufacturing and custom synthesis businesses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Overall, Divi&#8217;s Laboratories delivered a strong Q2 FY27 performance, with consolidated net profit rising more than 63% and EBITDA increasing 76% year-on-year.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source:<\/strong> Divi&#8217;s Laboratories Limited, unaudited consolidated financial results for the quarter and half year ended September 30, 2026, filed with the stock exchanges on November 7, 2026.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Disclaimer:<\/strong> Investments in the securities market are subject to market risks. Read all related documents carefully before investing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Do\u00a0you have a news tip for Lakshmishree reporters? Please email us at\u00a0<\/em>social@lakshmishree.com<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Divi&#8217;s Laboratories Limited reported a strong financial performance for the second quarter of FY27, with consolidated net profit increasing 63.6% year-on-year (YoY) to \u20b91,127 crore, compared with \u20b9689 crore in the corresponding quarter of the previous financial year. The pharmaceutical company&#8217;s revenue from operations grew 35.4% YoY to \u20b93,676 crore in Q2 FY27, against \u20b92,715 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[62,52,50],"tags":[1961,1960,642],"class_list":["post-9136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-results","category-daily-market-update","category-indian-market","tag-divis-laboratories","tag-divis-laboratories-q2-results","tag-q2-results"],"_links":{"self":[{"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/posts\/9136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/comments?post=9136"}],"version-history":[{"count":1,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/posts\/9136\/revisions"}],"predecessor-version":[{"id":9138,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/posts\/9136\/revisions\/9138"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/media\/9137"}],"wp:attachment":[{"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/media?parent=9136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/categories?post=9136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lakshmishree.com\/news\/wp-json\/wp\/v2\/tags?post=9136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}